Cargando…

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in H...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrati, Chiara, Castilletti, Concetta, Goletti, Delia, Sacchi, Alessandra, Bordoni, Veronica, Mariotti, Davide, Notari, Stefania, Matusali, Giulia, Meschi, Silvia, Petrone, Linda, Aiello, Alessandra, Najafi Fard, Saeid, Farroni, Chiara, Colavita, Francesca, Lapa, Daniele, Leone, Sara, Agresta, Alessandro, Capobianchi, Maria, Ippolito, Giuseppe, Vaia, Francesco, Puro, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034067/
https://www.ncbi.nlm.nih.gov/pubmed/35461335
http://dx.doi.org/10.1038/s41598-022-07741-z
_version_ 1784693033439068160
author Agrati, Chiara
Castilletti, Concetta
Goletti, Delia
Sacchi, Alessandra
Bordoni, Veronica
Mariotti, Davide
Notari, Stefania
Matusali, Giulia
Meschi, Silvia
Petrone, Linda
Aiello, Alessandra
Najafi Fard, Saeid
Farroni, Chiara
Colavita, Francesca
Lapa, Daniele
Leone, Sara
Agresta, Alessandro
Capobianchi, Maria
Ippolito, Giuseppe
Vaia, Francesco
Puro, Vincenzo
author_facet Agrati, Chiara
Castilletti, Concetta
Goletti, Delia
Sacchi, Alessandra
Bordoni, Veronica
Mariotti, Davide
Notari, Stefania
Matusali, Giulia
Meschi, Silvia
Petrone, Linda
Aiello, Alessandra
Najafi Fard, Saeid
Farroni, Chiara
Colavita, Francesca
Lapa, Daniele
Leone, Sara
Agresta, Alessandro
Capobianchi, Maria
Ippolito, Giuseppe
Vaia, Francesco
Puro, Vincenzo
author_sort Agrati, Chiara
collection PubMed
description Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.
format Online
Article
Text
id pubmed-9034067
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90340672022-04-25 Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine Agrati, Chiara Castilletti, Concetta Goletti, Delia Sacchi, Alessandra Bordoni, Veronica Mariotti, Davide Notari, Stefania Matusali, Giulia Meschi, Silvia Petrone, Linda Aiello, Alessandra Najafi Fard, Saeid Farroni, Chiara Colavita, Francesca Lapa, Daniele Leone, Sara Agresta, Alessandro Capobianchi, Maria Ippolito, Giuseppe Vaia, Francesco Puro, Vincenzo Sci Rep Article Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering. Nature Publishing Group UK 2022-04-23 /pmc/articles/PMC9034067/ /pubmed/35461335 http://dx.doi.org/10.1038/s41598-022-07741-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Agrati, Chiara
Castilletti, Concetta
Goletti, Delia
Sacchi, Alessandra
Bordoni, Veronica
Mariotti, Davide
Notari, Stefania
Matusali, Giulia
Meschi, Silvia
Petrone, Linda
Aiello, Alessandra
Najafi Fard, Saeid
Farroni, Chiara
Colavita, Francesca
Lapa, Daniele
Leone, Sara
Agresta, Alessandro
Capobianchi, Maria
Ippolito, Giuseppe
Vaia, Francesco
Puro, Vincenzo
Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
title Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
title_full Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
title_fullStr Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
title_full_unstemmed Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
title_short Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
title_sort persistent spike-specific t cell immunity despite antibody reduction after 3 months from sars-cov-2 bnt162b2-mrna vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034067/
https://www.ncbi.nlm.nih.gov/pubmed/35461335
http://dx.doi.org/10.1038/s41598-022-07741-z
work_keys_str_mv AT agratichiara persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT castilletticoncetta persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT golettidelia persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT sacchialessandra persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT bordoniveronica persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT mariottidavide persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT notaristefania persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT matusaligiulia persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT meschisilvia persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT petronelinda persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT aielloalessandra persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT najafifardsaeid persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT farronichiara persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT colavitafrancesca persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT lapadaniele persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT leonesara persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT agrestaalessandro persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT capobianchimaria persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT ippolitogiuseppe persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT vaiafrancesco persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT purovincenzo persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine
AT persistentspikespecifictcellimmunitydespiteantibodyreductionafter3monthsfromsarscov2bnt162b2mrnavaccine